Evotec SE Logo

Evotec SE

A drug discovery and development partner for pharma, biotech, and academia.

EVT | F

Overview

Corporate Details

ISIN(s):
DE0005664809 (+1 more)
LEI:
529900F9KI6OYITO9B12
Country:
Germany
Address:
Essener Bogen 7, 22419 Hamburg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Evotec SE is a life science company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies, as well as academic institutions. The company offers a fully integrated research and development value chain, leveraging proprietary technology platforms and deep disease understanding to accelerate the creation of new medicines. Its expertise spans multiple therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics subsidiary, the company also provides advanced solutions for the design, development, and manufacturing of biologics. Evotec operates through flexible partnership models, aiming to enhance the speed, efficiency, and quality of bringing novel treatments to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 12:07
Director's Dealing
Evotec SE: Paul Hitchin, buy
English 5.9 KB
2025-09-15 11:56
Declaration of Voting Results & Voting Rights Announcements
English 62.2 KB
2025-09-11 16:40
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.5 KB
2025-08-27 15:04
Director's Dealing
Evotec SE: Dr. Christian Wojczewski, buy
English 5.9 KB
2025-08-20 11:29
Declaration of Voting Results & Voting Rights Announcements
English 54.3 KB
2025-08-13 07:00
Earnings Release
Evotec SE reports H1 2025 results: Strong progress on strategy execution
English 18.4 KB
2025-08-13 00:00
Interim Report
Half-yearly financial report 2025
English 613.3 KB
2025-08-11 16:40
Declaration of Voting Results & Voting Rights Announcements
English 59.5 KB
2025-08-06 09:52
Report Publication Announcement
Evotec SE to announce first half-year results 2025 on 13 August 2025
English 11.3 KB
2025-07-30 07:16
M&A Activity
Evotec and Sandoz evolve their strategic partnership and agree on potential sal…
English 14.5 KB
2025-07-23 15:34
Declaration of Voting Results & Voting Rights Announcements
English 56.9 KB
2025-07-21 11:40
Earnings Release
Evotec adjusts revenue guidance and confirms profit guidance anticipating a mor…
English 13.3 KB
2025-07-15 11:35
Declaration of Voting Results & Voting Rights Announcements
English 56.9 KB
2025-06-30 11:00
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.4 KB
2025-06-25 07:30
Regulatory News Service
Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular underst…
English 16.4 KB

Automate Your Workflow. Get a real-time feed of all Evotec SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Evotec SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-06 Dohrmann, Dr. Cord Board Other None 91,363.32 EUR
2024-10-01 Rouxel, Laetitia Board Other None 58,396.84 EUR
2024-09-13 Wojczewski, Dr. Christian Board Buy None 61,087.50 EUR
2024-09-05 Dalbiez, Aurélie Board Buy None 21,202.55 EUR
2024-09-02 Wojczewski, Dr. Christian Board Buy None 64,466.00 EUR
2024-08-29 Löw-Friedrich, Prof. Dr. Iris Supervisory board Buy None 100,050.00 EUR
2024-08-23 Wojczewski, Dr. Christian Board Buy None 113,291.94 EUR
2024-08-22 Johnstone, Dr. Craig Board Buy None 16,553.03 EUR
2024-08-19 Wojczewski, Dr. Christian Board Buy None 59,766.00 EUR
2024-05-03 Dohrmann, Dr. Cord Board Other None 76,220.10 EUR

Peer Companies

Company Country Ticker View
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS
SKINBIOTHERAPEUTICS PLC Logo
A life science company developing microbiome-based skin health products and supplements.
United Kingdom SBTX
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.